Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3
about
Molecular integrity and global gene expression of breast and lung cancer stem cells under long-term storage and recoveryDetection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways.FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signalingCancer translocations in human cells induced by zinc finger and TALE nucleasesHDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.STAT3: a multifaceted oncogene.Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOSCrizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphomaStaphylococcal enterotoxin B in vivo modulates both gamma interferon receptor expression and ligand-induced activation of signal transducer and activator of transcription 1 in T cells.Nonredundant roles for Stat5a/b in directly regulating Foxp3Pathobiology of ALK+ anaplastic large-cell lymphoma.Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional ActivityCPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growthSensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma.Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress.Role of Stat3 in suppressing anti-tumor immunity.EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3Targeting ALK in neuroblastoma--preclinical and clinical advancements.Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomasSTAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.STAT3: a target to enhance antitumor immune response.The four types of Tregs in malignant lymphomas.ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictionsPeripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications.The novel role of pyrvinium in cancer therapy.Atractylodin Inhibits Interleukin-6 by Blocking NPM-ALK Activation and MAPKs in HMC-1.Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration.Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer.Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogrammingMechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
P2860
Q30454378-3D5D703B-C83F-44F9-A68D-26927D943CA6Q33898865-EF2B3CA7-117A-438E-887F-EFA88E872EC5Q33953115-FB4DA488-C202-4BDB-BCF9-99D0E944C29BQ34459845-91A924BC-448D-44A3-B7D4-C66625C9AC02Q34660198-20BB7FAC-CB93-43A1-BC35-A77A12F1858EQ34707183-7430A722-AB88-4730-B413-B8CF3765437AQ34771828-6FD11BB9-FE98-44FD-B950-6CA450967B71Q35013758-88B90B25-FA19-41A3-B449-4B9C999C3377Q35123227-9ADA12F6-EEBF-4A9D-8F7E-E0C406F37A72Q35220408-BAE27FE6-8EA5-4E3D-8DAD-4A9E05971B6AQ35285497-E06AB5C8-C168-4307-81F8-1D7D10A59FA1Q35688987-88C452B4-1E25-4778-9F0F-53F7310230A5Q35828667-2C5BAAB0-C8C6-4E62-9A87-724CA8F7CB58Q36007756-A37F8DC1-D472-4875-BDB9-48B2F4006340Q36033384-9187560E-7491-4660-BF65-A6523B730A56Q36082118-351DA55F-EACE-4279-948B-BEFEA94B9401Q36106068-D38777A3-99B7-4DE8-A748-B76BE3B396E1Q36145016-B6DFBD3F-107E-42DC-B69D-0C51DC1475B1Q36177932-C0E3058D-CEF9-467F-B82C-D7B0B24D88E5Q36345656-690A0E45-4D59-448D-A2EC-B3474C0CAF44Q36511310-4FF4DB38-1B5F-4DED-8DD5-C111C07887E8Q36797504-1A4E3CE8-968E-422F-8156-7E2DDED01833Q36821217-49A811AD-DC36-4E03-87D9-11D715B7CD96Q36933081-6BB884E3-E946-499F-AB61-8F027AC8A165Q36982497-D8D2E105-E01C-4700-873A-F7F5C6595B08Q37081609-4944D181-34F8-4BFF-A58A-61A17905040FQ37174303-5A2E21F8-EE31-415F-82E2-C8214C1C5E82Q37485330-9D1CCE81-31EF-446A-8CBE-A03323E42096Q37576259-99CFD3DC-A779-4B64-B801-47F737E31E06Q37762206-46C8D223-17DD-42A6-9E6E-7A480B3BBD10Q37966000-78D47381-F852-449F-8B07-B83BCE80190CQ38010052-58813F6A-D294-4D87-87EB-C2F29A11B729Q38022591-1A0CD315-3744-4C59-9D00-0ADC8CA6E079Q38289038-37D878F2-402D-4B16-AB95-189B8BC38E7FQ38684406-2F2B9583-ECF1-4468-A44E-983919B8A04DQ38748088-92437D47-5AB9-4832-99F5-6410F0B8C7AFQ38932729-D658D6C4-13EF-405B-9306-101BFB4E6C9CQ38998862-1E57FF67-6230-4530-A777-F2C74AC3B497Q39064213-DA28FB0F-729D-4EE2-9873-927FE2B3676CQ39237785-5DA83535-C5B1-4BB9-B394-63A7AB8AE7FF
P2860
Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Nucleophosmin/anaplastic lymph ...... phenotype by activating STAT3
@ast
Nucleophosmin/anaplastic lymph ...... phenotype by activating STAT3
@en
Nucleophosmin/anaplastic lymphoma kinase
@nl
type
label
Nucleophosmin/anaplastic lymph ...... phenotype by activating STAT3
@ast
Nucleophosmin/anaplastic lymph ...... phenotype by activating STAT3
@en
Nucleophosmin/anaplastic lymphoma kinase
@nl
prefLabel
Nucleophosmin/anaplastic lymph ...... phenotype by activating STAT3
@ast
Nucleophosmin/anaplastic lymph ...... phenotype by activating STAT3
@en
Nucleophosmin/anaplastic lymphoma kinase
@nl
P2093
P2860
P356
P1476
Nucleophosmin/anaplastic lymph ...... phenotype by activating STAT3
@en
P2093
Mariusz A Wasik
Michal Marzec
Monika Kasprzycka
Qian Zhang
Xiaobin Liu
P2860
P304
P356
10.1073/PNAS.0603507103
P407
P577
2006-06-09T00:00:00Z